April 21st 2023
Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.
February 6th 2023
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.
December 26th 2022
This year's most-read cancer news included researchers finding a possible liver cancer immunotherapy, cancer patients facing many negative impacts from COVID-19 and more.
December 8th 2022
The researchers have several suggestions for how harm from screening should be reported in screening guidelines.
November 14th 2022
Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.
Get a Cancer Gene Test? A Tool for Helping to Decide
Dana-Farber Cancer Institute tool evaluates the probability of having
genetic mutations that confer elevated risk for 18 cancers.
Price and End Points. For Cancer Drugs, There Is a Disconnect, Research Finds
Overall survival is considered a more definitive end point. But according to Vinay Prasad, M.D., M.P.H., and colleagues , drugs approved based on progression-free survival and overall response rate were priced higher than those approved based on overall survival.
Up, Up and Not Going Away: Cancer Drug Prices
Escalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.
The Latest on CAR-T Therapy
More of these treatments have been approved, but supply chain issues and cost remain obstacles.
The Oncology Care Model and Its Successor
Although the Oncology Care Model produced some positive results, the value-based care model cost Medicare money. Now attention is turning to its successor, the Enhancing Oncology Model.
CAR-T Therapy for Multiple Myeloma Is on the Horizon
Bispecific antibody therapies are also in development.
Researchers Identify a Communications Breakdown Over Herceptin Biosimilars
If biosimilar acceptance is to grow, it’s going to take a great deal of work to improve the levels of trust between payers, patients, and oncologists.
Reframing Race and Cancer
Research and discussion about the high cancer rates among Black Americans used to be dominated by genetics and the search for biological differences. Now attention has shifted to the social determinants of health.
Has the Pendulum Swung Too Far Against the Use of Opioids?
Patients with cancer who have a poor prognosis may face obstacles in accessing critical pain medications.
Cancer Mortality is Decreasing in the U.S.
The American Cancer Society’s 2022 statistical report shows that the 30-year trend is continuing.
Biden Relaunches Cancer Moonshot to “End Cancer as We Know It”
Biden is reviving the program he headed as vice president with the goal of reducing the cancer mortality rate and improving the experience of patients and their loved ones.
VA Hospital Improves Timeliness of HCC Diagnosis, Treatment With Electronic Tracking System
The introduction of an electronic tracking system decreased the time from hepatocellular carcinoma (HCC) diagnosis to treatment by more than a month.
Billions Flowing into the Cancer Immunotherapy Market
The global cancer immunotherapy market is set to grow at a compound annual growth rate, or CAGR, of 12.6% to $277.1 billion by 2030.
Immunotherapy, Precision Medicine are Coming on Strong in Oncology
But the future of value-based care in oncology is uncertain with no certain successor to the Oncology Care Model in sight.
With High Deductible Health Plans, Cancer Patients are Paying More, Study Finds
Patients with a variety of cancers spent much more money out of their own pocket than those in traditional plans. Some may be delaying treatment due to higher costs.
Location, Location, Location. That Also Applies to Cancer Treatment.
Site of service has a major effect on the cost. Home infusion and oral formulations are challenging both hospital- and physician-based infusions.
JAMA Study: Oncology Care Model Cost Medicare $315.6 Million
Per episode saving of $297 during the first three years of the value-based care model were offset by $704 in payments for enhanced services to the 201 participating practices, study finds.
FDA Updates for the Week of October 11, 2021
In COVID-19 news: An advisory committee recommends both J&J's and Moderna’s booster, Regeneron seeks full approved for its treatment and Merck seeks EUA for treatment. In cancer, the FDA approves Verzenio for early breast cancer, Keytruda for advanced cervical cancer, and Tecentriq in early nonsmall cell lung cancer.
FDA Updates for the Week of Oct. 4, 2021
Pfizer officially seeks EUA for pediatric COVID vaccine, AstraZeneca seeks EU for COVID-19 prevention, J&J submits data for COVID-19 booster, a gene therapy is approved for leukemia, and Janssen submits Stelara for psoriatic arthritis in children.
Oncology: Network Adequacy Rules for Cancer Care are Often Inadequate
Many states only have vaguely worded qualitative standards for network adequacy for cancer care. Others have quantitative standards based on distance or waiting time.
Study Suggests Berzosertib Does Not Benefit Metastatic Bladder Cancer Patients
A recent City of Hope study claims a therapy that combines a drug that disrupts DNA repair with chemotherapy cisplatin and gemcitabine does not prolong progression-free survival for patients with urothelial cancer.
Feasibility Study Shows Mobile Devices Help Patients Communicate Cancer Treatment Effects
Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.
FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo
Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.
Financial Incentives Result in Small Increase in CRC Screening
Study results reported in JAMA Network Open show that financial incentives are only modestly effective in getting more people to get way screened for colorectal cancer.
FDA Updates: Opdivo, Jardiance and Jemperli Get Nods for New Indications
FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.
Never Too Late To Quit: Smoking Cessation Pays Off for NSCLC Patients
Study shows that nonsmall cell lung cancer patients who smoke but quit after their diagnosis have better overall survival, progression-free survival than patients who continue to smoke.
FDA Updates: Merck’s Pneumococcal Vaccine Leads the Week
New vaccine for pneumococcal disease, an sNDA approved based on real-world data, a new therapy for skin and muscle disease, Keytruda combination receives full approval in endometrial cancer, a new diabetes therapy is approved, and another JAK inhibitor misses PDUFA date round out this week’s FDA news.
A Number of Cancer Patients Desire Greater Involvement in Treatment Decisions as a Result of COVID-19 and They Can Have It
Sixty percent of patients likely to move forward with a healthcare decision not recommended by their physician, according to a TrialJectory Survey.
Best Practices to Define, Care for Lung Cancer
When wondering what step to take first after learning of your cancer diagnosis, assembling the right care team and creating a treatment plan designed uniquely is important to get you on the right track. Comprehensive biomarker testing can then help identify your type of lung cancer and help move steps forward for proper care.
With Accelerated Approval Pathway, Risk of Withdrawal Looms
The FDA’s accelerated pathway gets drugs to market quickly, but it also can mean patients are put on therapies that do not actually provide a clinical benefit.
2 Clarke Drive Cranbury, NJ 08512